vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Postal Realty Trust, Inc. (PSTL). Click either name above to swap in a different company.
Postal Realty Trust, Inc. is the larger business by last-quarter revenue ($26.0M vs $16.1M, roughly 1.6× Journey Medical Corp). Postal Realty Trust, Inc. runs the higher net margin — 17.9% vs -7.8%, a 25.6% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 21.7%). Over the past eight quarters, Postal Realty Trust, Inc.'s revenue compounded faster (22.6% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Postal Realty Trust, Inc. is a specialized real estate investment trust that acquires, owns, and manages properties primarily leased to the United States Postal Service. Its portfolio includes last-mile postal facilities, sorting centers, and retail post office locations across the U.S., supporting critical mail and package delivery infrastructure.
DERM vs PSTL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $26.0M |
| Net Profit | $-1.2M | $4.6M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 39.2% |
| Net Margin | -7.8% | 17.9% |
| Revenue YoY | 27.3% | 21.7% |
| Net Profit YoY | -182.0% | 3.1% |
| EPS (diluted) | $-0.04 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $26.0M | ||
| Q3 25 | $17.0M | $24.3M | ||
| Q2 25 | $15.0M | $23.4M | ||
| Q1 25 | $13.1M | $22.1M | ||
| Q4 24 | $12.6M | $21.4M | ||
| Q3 24 | $14.6M | $19.7M | ||
| Q2 24 | $14.9M | $18.1M | ||
| Q1 24 | $13.0M | $17.3M |
| Q4 25 | $-1.2M | $4.6M | ||
| Q3 25 | $-2.3M | $3.8M | ||
| Q2 25 | $-3.8M | $3.6M | ||
| Q1 25 | $-4.1M | $2.1M | ||
| Q4 24 | $1.5M | $4.5M | ||
| Q3 24 | $-2.4M | $1.1M | ||
| Q2 24 | $-3.4M | $817.0K | ||
| Q1 24 | $-10.4M | $206.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 39.2% | ||
| Q3 25 | -9.0% | 37.6% | ||
| Q2 25 | -19.2% | 37.3% | ||
| Q1 25 | -25.3% | 28.4% | ||
| Q4 24 | 17.7% | 43.2% | ||
| Q3 24 | -19.8% | 24.3% | ||
| Q2 24 | -19.7% | 22.8% | ||
| Q1 24 | -77.4% | 17.6% |
| Q4 25 | -7.8% | 17.9% | ||
| Q3 25 | -13.6% | 15.7% | ||
| Q2 25 | -25.3% | 15.5% | ||
| Q1 25 | -31.0% | 9.4% | ||
| Q4 24 | 12.1% | 21.1% | ||
| Q3 24 | -16.3% | 5.4% | ||
| Q2 24 | -22.6% | 4.5% | ||
| Q1 24 | -80.1% | 1.2% |
| Q4 25 | $-0.04 | $0.16 | ||
| Q3 25 | $-0.09 | $0.13 | ||
| Q2 25 | $-0.16 | $0.12 | ||
| Q1 25 | $-0.18 | $0.06 | ||
| Q4 24 | $0.10 | $0.17 | ||
| Q3 24 | $-0.12 | $0.03 | ||
| Q2 24 | $-0.17 | $0.02 | ||
| Q1 24 | $-0.53 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $1.5M |
| Total DebtLower is stronger | $25.3M | $361.1M |
| Stockholders' EquityBook value | $31.9M | $285.2M |
| Total Assets | $94.6M | $759.1M |
| Debt / EquityLower = less leverage | 0.79× | 1.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $1.5M | ||
| Q3 25 | $24.9M | $1.9M | ||
| Q2 25 | $20.3M | $1.1M | ||
| Q1 25 | $21.1M | $639.0K | ||
| Q4 24 | $20.3M | $1.8M | ||
| Q3 24 | $22.5M | $970.0K | ||
| Q2 24 | $23.9M | $1.7M | ||
| Q1 24 | $24.1M | $1.9M |
| Q4 25 | $25.3M | $361.1M | ||
| Q3 25 | $25.2M | $347.0M | ||
| Q2 25 | $25.1M | $328.8M | ||
| Q1 25 | $25.0M | $306.7M | ||
| Q4 24 | $24.9M | $296.7M | ||
| Q3 24 | $19.8M | $277.0M | ||
| Q2 24 | $19.7M | $273.7M | ||
| Q1 24 | $14.7M | $247.6M |
| Q4 25 | $31.9M | $285.2M | ||
| Q3 25 | $25.9M | $273.9M | ||
| Q2 25 | $19.2M | $250.8M | ||
| Q1 25 | $21.5M | $245.5M | ||
| Q4 24 | $20.1M | $251.3M | ||
| Q3 24 | $10.9M | $245.6M | ||
| Q2 24 | $11.3M | $245.5M | ||
| Q1 24 | $13.0M | $248.1M |
| Q4 25 | $94.6M | $759.1M | ||
| Q3 25 | $85.2M | $735.2M | ||
| Q2 25 | $81.2M | $689.8M | ||
| Q1 25 | $85.0M | $654.0M | ||
| Q4 24 | $80.2M | $646.8M | ||
| Q3 24 | $64.0M | $615.1M | ||
| Q2 24 | $65.2M | $608.2M | ||
| Q1 24 | $66.6M | $584.1M |
| Q4 25 | 0.79× | 1.27× | ||
| Q3 25 | 0.97× | 1.27× | ||
| Q2 25 | 1.30× | 1.31× | ||
| Q1 25 | 1.16× | 1.25× | ||
| Q4 24 | 1.24× | 1.18× | ||
| Q3 24 | 1.81× | 1.13× | ||
| Q2 24 | 1.75× | 1.11× | ||
| Q1 24 | 1.13× | 1.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $44.5M |
| Free Cash FlowOCF − Capex | — | $37.6M |
| FCF MarginFCF / Revenue | — | 144.5% |
| Capex IntensityCapex / Revenue | — | 26.7% |
| Cash ConversionOCF / Net Profit | — | 9.59× |
| TTM Free Cash FlowTrailing 4 quarters | — | $65.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $44.5M | ||
| Q3 25 | $-2.4M | $10.9M | ||
| Q2 25 | $-942.0K | $11.4M | ||
| Q1 25 | $-2.8M | $10.8M | ||
| Q4 24 | $2.2M | $33.5M | ||
| Q3 24 | $-1.2M | $8.0M | ||
| Q2 24 | $-5.2M | $9.9M | ||
| Q1 24 | $-5.0M | $6.4M |
| Q4 25 | — | $37.6M | ||
| Q3 25 | — | $8.8M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.2M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $7.4M | ||
| Q2 24 | — | $8.9M | ||
| Q1 24 | — | $5.8M |
| Q4 25 | — | 144.5% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 38.8% | ||
| Q1 25 | — | 45.9% | ||
| Q4 24 | — | 143.8% | ||
| Q3 24 | — | 37.6% | ||
| Q2 24 | — | 49.4% | ||
| Q1 24 | — | 33.6% |
| Q4 25 | — | 26.7% | ||
| Q3 25 | — | 8.9% | ||
| Q2 25 | — | 10.1% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.4% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | — | 9.59× | ||
| Q3 25 | — | 2.87× | ||
| Q2 25 | — | 3.16× | ||
| Q1 25 | — | 5.20× | ||
| Q4 24 | 1.46× | 7.44× | ||
| Q3 24 | — | 7.48× | ||
| Q2 24 | — | 12.10× | ||
| Q1 24 | — | 31.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
PSTL
Segment breakdown not available.
